Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Pigment Cell Melanoma Res. 2015 Sep;28(5):590–598. doi: 10.1111/pcmr.12392

Figure 3.

Figure 3

RAC1 expression does not affect sensitivity to MEK inhibition. (A) Melan-a RAC1 WT, melan-a RAC1 P29S, and melan-a RAC1 Q61L cells were cultured in 3D collagen and treated with trametinib (90 nm) for 48 h. Cells were stained with annexin V and analyzed by flow cytometry (n = 3; errors bars, SE). (B) WM1346 TR and WM1361A TR cells with tetracycline-inducible expression of RAC1 WT, RAC1 P29S, and RAC1 Q61L were treated with dox for 72 h. Cells were lysed and lysates analyzed by Western blot. (C) WM1346 TR and WM1361A TR cells with inducible expression of RAC1 WT, RAC1 P29S, and RAC1 Q61L cells were pretreated with dox for 72 h. Cells were then cultured in 3D collagen and treated as in (A). (D) YUHEF cells were transfected with non-targeting or RAC1-targeting siRNA, and after 72 h, cells were lysed and lysates analyzed by Western blot. (E) YUHEF cells were transfected as in (D), cultured in 3D collagen, and treated as in (A).